Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Direct Lineage Reprogramming of A1 Astrocytes
EF 2021-22
Résumé
Central Nervous System (CNS) disorders and injuries affecting the brain and spinal cord are one of the leading causes of disability worldwide. Common to many types of CNS disease, is the loss of myelin, also known as ;demyelination. Myelin is made up of cells called oligodendrocytes, which form a protective and insulating coating around nerve cells that is required for efficient brain signalling. Currently, there are limited treatment options for demyelinating disease. This highlights the need for novel therapeutics. In hopes of curing demyelinating diseases, scientists have been trying to develop therapies to replace oligodendrocytes. An exciting new therapeutic strategy is the conversion of resident brain cells, called astrocytes, into new oligodendrocytes. This approach allows the removal of certain types of astrocytes that can take on harmful forms and cause further damage or disease. In this study, we will investigate whether we can convert a particular type of astrocytes, called A1, that have been shown to kill oligodendrocytes. We will also investigate the biology that underlies this process, specifically the genes that drive the conversion, in order to better understand and optimize this therapy. If successful, this novel reprogramming strategy will eliminate disease-causing astrocytes while simultaneously replacing healthy oligodendrocytes that are lost in CNS disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466708
Name
Taha Hiba
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Direct Lineage Reprogramming of A1 Astrocytes
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Astrocyte; Culture; Differentiation; Myelination; Neurotoxic; Oligodendrocyte; Reprogramming; Sequencing; Sex; Transcriptomics
Abstract
Central Nervous System (CNS) disorders and injuries affecting the brain and spinal cord are one of the leading causes of disability worldwide. Common to many types of CNS disease, is the loss of myelin, also known as ;demyelination. Myelin is made up of cells called oligodendrocytes, which form a protective and insulating coating around nerve cells that is required for efficient brain signalling. Currently, there are limited treatment options for demyelinating disease. This highlights the need for novel therapeutics. In hopes of curing demyelinating diseases, scientists have been trying to develop therapies to replace oligodendrocytes. An exciting new therapeutic strategy is the conversion of resident brain cells, called astrocytes, into new oligodendrocytes. This approach allows the removal of certain types of astrocytes that can take on harmful forms and cause further damage or disease. In this study, we will investigate whether we can convert a particular type of astrocytes, called A1, that have been shown to kill oligodendrocytes. We will also investigate the biology that underlies this process, specifically the genes that drive the conversion, in order to better understand and optimize this therapy. If successful, this novel reprogramming strategy will eliminate disease-causing astrocytes while simultaneously replacing healthy oligodendrocytes that are lost in CNS disease.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Taha, Hiba
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~